Published in Curr Opin HIV AIDS on July 01, 2011
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science (2013) 8.24
HIV prevention transformed: the new prevention research agenda. Lancet (2011) 4.23
Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? Lancet (2013) 2.31
Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. AIDS (2013) 2.17
HIV treatment as prevention and HPTN 052. Curr Opin HIV AIDS (2012) 1.97
Disparities in HIV transmission risk among HIV-infected black and white men who have sex with men, United States, 2009. AIDS (2014) 1.77
HIV treatment as prevention: debate and commentary--will early infection compromise treatment-as-prevention strategies? PLoS Med (2012) 1.76
Combination prevention: new hope for stopping the epidemic. Curr HIV/AIDS Rep (2013) 1.36
Perceived acceptability of home-based couples voluntary HIV counseling and testing in Northern Tanzania. AIDS Care (2011) 1.23
Can combination prevention strategies reduce HIV transmission in generalized epidemic settings in Africa? The HPTN 071 (PopART) study plan in South Africa and Zambia. J Acquir Immune Defic Syndr (2013) 1.23
Translation of biomedical prevention strategies for HIV: prospects and pitfalls. J Acquir Immune Defic Syndr (2013) 1.12
Phylogenetic inferences on HIV-1 transmission: implications for the design of prevention and treatment interventions. AIDS (2013) 1.10
Effects of syndemics on HIV viral load and medication adherence in the multicentre AIDS cohort study. AIDS (2015) 0.91
Clinical uncertainties, health service challenges, and ethical complexities of HIV "test-and-treat": a systematic review. Am J Public Health (2013) 0.90
Future of phylogeny in HIV prevention. J Acquir Immune Defic Syndr (2013) 0.85
Incorporating couples-based approaches into HIV prevention for gay and bisexual men: opportunities and challenges. Arch Sex Behav (2014) 0.85
Global HIV epidemiology: A guide for strategies in prevention and care. Curr HIV/AIDS Rep (2014) 0.85
Evaluating the Impact of Test-and-Treat on the HIV Epidemic among MSM in China Using a Mathematical Model. PLoS One (2015) 0.85
The Opposites Attract Study of viral load, HIV treatment and HIV transmission in serodiscordant homosexual male couples: design and methods. BMC Public Health (2014) 0.84
Alcohol and drug use outcomes among vulnerable women living with HIV: results from the Western Cape Women's Health CoOp. AIDS Care (2014) 0.82
HIV partner notification: possible and essential. Sex Transm Dis (2013) 0.79
HIV care and treatment experiences among female sex workers living with HIV in sub-Saharan Africa: A systematic review. Afr J AIDS Res (2016) 0.79
HIV testing and engagement in care among highly vulnerable female sex workers: implications for treatment as prevention models. J Health Care Poor Underserved (2014) 0.78
The indirect impact of antiretroviral therapy: Mortality risk, mental health, and HIV-negative labor supply. J Health Econ (2015) 0.77
Epidemiological impact of achieving UNAIDS 90-90-90 targets for HIV care in India: a modelling study. BMJ Open (2016) 0.77
Systems mapping of HIV-1 infection. BMC Genet (2012) 0.76
A practical online tool to estimate antiretroviral coverage for HIV infected and susceptible populations needed to reduce local HIV epidemics. Sci Rep (2016) 0.75
Willingness to Act upon Beliefs about 'Treatment as Prevention' among Australian Gay and Bisexual Men. PLoS One (2016) 0.75
HIV-Risk Reduction with Juvenile Offenders on Probation. J Child Fam Stud (2015) 0.75
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med (2010) 50.17
Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med (2000) 41.18
Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet (2008) 36.01
Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science (2010) 35.19
Estimation of HIV incidence in the United States. JAMA (2008) 21.27
Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis (2005) 21.08
Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet (2010) 16.90
Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet (2010) 12.82
Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One (2010) 10.39
Changes in sexual behavior and risk of HIV transmission after antiretroviral therapy and prevention interventions in rural Uganda. AIDS (2006) 9.45
Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science (2004) 8.60
The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet (2006) 7.17
Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med (2007) 7.14
HIV status in discordant couples in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Infect Dis (2010) 6.95
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis (2008) 6.73
HIV-1 transmission, by stage of infection. J Infect Dis (2008) 6.57
Impact of highly active antiretroviral treatment on HIV seroincidence among men who have sex with men: San Francisco. Am J Public Health (2002) 6.01
Virologic and immunologic determinants of heterosexual transmission of human immunodeficiency virus type 1 in Africa. AIDS Res Hum Retroviruses (2001) 6.00
Relation between HIV viral load and infectiousness: a model-based analysis. Lancet (2008) 5.74
Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J Acquir Immune Defic Syndr (2005) 4.96
Combined antiretroviral treatment and heterosexual transmission of HIV-1: cross sectional and prospective cohort study. BMJ (2010) 4.75
Decline in HIV infectivity following the introduction of highly active antiretroviral therapy. AIDS (2004) 4.64
Treatment to prevent transmission of HIV-1. Clin Infect Dis (2010) 4.54
HIV-1 transmission among HIV-1 discordant couples before and after the introduction of antiretroviral therapy. AIDS (2011) 4.26
Decreased HIV transmission after a policy of providing free access to highly active antiretroviral therapy in Taiwan. J Infect Dis (2004) 4.17
Characterization of V3 sequence heterogeneity in subtype C human immunodeficiency virus type 1 isolates from Malawi: underrepresentation of X4 variants. J Virol (1999) 4.16
Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med (2008) 4.12
The role of early HIV infection in the spread of HIV through populations. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 3.75
Molecular epidemiology of human immunodeficiency virus type 1 transmission in a heterosexual cohort of discordant couples in Zambia. J Virol (2002) 3.58
High levels of human immunodeficiency virus type 1 in blood and semen of seropositive men in sub-Saharan Africa. J Infect Dis (1998) 3.46
Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic. J Infect Dis (2008) 3.38
Population-based HIV-1 incidence in France, 2003-08: a modelling analysis. Lancet Infect Dis (2010) 3.01
The contribution of HIV-discordant relationships to new HIV infections in Rakai, Uganda. AIDS (2011) 2.94
Persistent HIV RNA shedding in semen despite effective antiretroviral therapy. AIDS (2009) 2.77
The cost-effectiveness and population outcomes of expanded HIV screening and antiretroviral treatment in the United States. Ann Intern Med (2010) 2.71
Per-contact probability of HIV transmission in homosexual men in Sydney in the era of HAART. AIDS (2010) 2.65
Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis (2009) 2.60
Modelling the effect of combination antiretroviral treatments on HIV incidence. AIDS (2001) 2.48
Male viral load and heterosexual transmission of HIV-1 subtype E in northern Thailand. J Acquir Immune Defic Syndr (2002) 2.48
Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis (2010) 2.45
Heterosexual transmission of HIV-1 is associated with high plasma viral load levels and a positive viral isolation in the infected partner. J Acquir Immune Defic Syndr (1999) 2.36
Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load. AIDS (2010) 2.33
Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr (2009) 2.32
Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa. PLoS One (2010) 2.30
Ongoing HIV-1 transmission among men who have sex with men in Amsterdam: a 25-year prospective cohort study. AIDS (2011) 2.28
Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis (2010) 2.28
Frequency and determinants of unprotected sex among HIV-infected persons: the Swiss HIV cohort study. Clin Infect Dis (2010) 2.12
The unexpected movement of the HIV epidemic in the Southeastern United States: transmission among college students. J Acquir Immune Defic Syndr (2005) 1.93
Role of acute and early HIV infection in the sexual transmission of HIV. Curr Opin HIV AIDS (2010) 1.89
Increase in sexually transmitted infections among homosexual men in Amsterdam in relation to HAART. Sex Transm Infect (2001) 1.76
Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission. Arch Intern Med (1994) 1.72
Role of viral load in heterosexual transmission of human immunodeficiency virus type 1 by blood transfusion recipients. Transfusion Safety Study Group. Am J Epidemiol (1997) 1.62
The pharmacokinetics and viral activity of tenofovir in the male genital tract. J Acquir Immune Defic Syndr (2008) 1.55
Human immunodeficiency virus type 1 genomic RNA sequences in the female genital tract and blood: compartmentalization and intrapatient recombination. J Virol (2005) 1.53
HIV-1 Populations in Semen Arise through Multiple Mechanisms. PLoS Pathog (2010) 1.47
Inhibition of human immunodeficiency virus type 1 infection by the candidate microbicide dapivirine, a nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother (2008) 1.46
Continued high risk sexual behavior following diagnosis with acute HIV infection in South Africa and Malawi: implications for prevention. AIDS Behav (2011) 1.41
Oral preexposure prophylaxis for HIV--another arrow in the quiver? N Engl J Med (2010) 1.40
HIV-1 subtype C-infected individuals maintaining high viral load as potential targets for the "test-and-treat" approach to reduce HIV transmission. PLoS One (2010) 1.36
Sexual transmission of HIV-1 among serodiscordant couples in Porto Alegre, southern Brazil. Sex Transm Dis (2008) 1.28
Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. J Infect Dis (2010) 1.26
Pharmacologic opportunities for HIV prevention. Clin Pharmacol Ther (2010) 1.19
Male genital tract compartmentalization of human immunodeficiency virus type 1 (HIV). AIDS Res Hum Retroviruses (2008) 1.18
Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complex. JAMA (1988) 1.15
HIV treatment as prevention and "the Swiss statement": in for a dime, in for a dollar? Clin Infect Dis (2010) 1.06
Differential extracellular and intracellular concentrations of zidovudine and lamivudine in semen and plasma of HIV-1-infected men. J Acquir Immune Defic Syndr (2008) 1.02
Detection of human immunodeficiency virus (HIV) type 1 M184V and K103N minority variants in patients with primary HIV infection. Antimicrob Agents Chemother (2009) 1.01
HIV infection of the male genital tract--consequences for sexual transmission and reproduction. Int J Androl (2009) 1.01
Pathophysiology of HIV-1 in semen: current evidence for compartmentalisation and penetration by antiretroviral drugs. Curr HIV Res (2005) 1.01
The effect of transmitted HIV-1 drug resistance on pre-therapy viral load. AIDS (2010) 1.01
Reducing sexual risk behavior among steady heterosexual serodiscordant couples in a testing and counseling program. Sex Transm Dis (2009) 0.97
Transmitted drug resistance and type of infection in newly diagnosed HIV-1 individuals in Honduras. J Clin Virol (2010) 0.96
Is antiretroviral therapy modifying the HIV epidemic? Lancet (2010) 0.90
Modelling the impact of treatment with individual antiretrovirals. Curr Opin HIV AIDS (2011) 0.87
Introduction to recent developments in HIV epidemic modeling. Curr Opin HIV AIDS (2011) 0.84
Low prevalence of transmitted drug resistance among newly diagnosed HIV-1 patients in Latvia. J Med Virol (2010) 0.84
Is antiretroviral therapy modifying the HIV epidemic? Lancet (2010) 0.83
Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci U S A (2008) 16.54
Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis (2004) 8.30
Detection of acute infections during HIV testing in North Carolina. N Engl J Med (2005) 7.60
Narrative review: antiretroviral therapy to prevent the sexual transmission of HIV-1. Ann Intern Med (2007) 7.14
The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol (2004) 7.04
Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med (2009) 7.01
Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women. Lancet (2011) 6.91
Penetration of tenofovir and emtricitabine in mucosal tissues: implications for prevention of HIV-1 transmission. Sci Transl Med (2011) 6.79
The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J Exp Med (2009) 6.22
The role of acute and early HIV infection in the spread of HIV and implications for transmission prevention strategies in Lilongwe, Malawi: a modelling study. Lancet (2011) 5.87
Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. Lancet Infect Dis (2008) 5.85
Syphilis in China: results of a national surveillance programme. Lancet (2007) 5.76
Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA (2004) 5.66
Population-based study of chlamydial infection in China: a hidden epidemic. JAMA (2003) 5.40
Pre-exposure prophylaxis for HIV prevention: how to predict success. Lancet (2011) 5.34
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis. AIDS (2007) 4.89
HIV/AIDS risk among brothel-based female sex workers in China: assessing the terms, content, and knowledge of sex work. Sex Transm Dis (2004) 4.88
AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science (2005) 4.44
HIV prevention transformed: the new prevention research agenda. Lancet (2011) 4.23
Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78
Amplified transmission of HIV-1: comparison of HIV-1 concentrations in semen and blood during acute and chronic infection. AIDS (2007) 3.72
High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men. PLoS Pathog (2010) 3.68
Surplus men, sex work, and the spread of HIV in China. AIDS (2005) 3.64
Trichomonas vaginalis infection in male sexual partners: implications for diagnosis, treatment, and prevention. Clin Infect Dis (2006) 3.17
Detection of acute HIV infection: a field evaluation of the determine® HIV-1/2 Ag/Ab combo test. J Infect Dis (2011) 3.16
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10
HIV partner notification is effective and feasible in sub-Saharan Africa: opportunities for HIV treatment and prevention. J Acquir Immune Defic Syndr (2011) 2.49
Rapid, real-time detection of acute HIV infection in patients in Africa. J Infect Dis (2006) 2.44
Frequent detection of acute primary HIV infection in men in Malawi. AIDS (2004) 2.43
Simultaneous quantification of emtricitabine and tenofovir in human plasma using high-performance liquid chromatography after solid phase extraction. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 2.38
Maraviroc concentrates in the cervicovaginal fluid and vaginal tissue of HIV-negative women. J Acquir Immune Defic Syndr (2009) 2.32
The prevalence of trichomoniasis in young adults in the United States. Sex Transm Dis (2005) 2.31
Prostate-specific antigen to ascertain reliability of self-reported coital exposure to semen. Sex Transm Dis (2006) 2.31
Antiretroviral treatment of HIV-1 prevents transmission of HIV-1: where do we go from here? Lancet (2013) 2.31
Acute HIV revisited: new opportunities for treatment and prevention. J Clin Invest (2004) 2.30
Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A (2012) 2.27
China's syphilis epidemic: a systematic review of seroprevalence studies. Sex Transm Dis (2006) 2.23
Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed Chromatogr (2007) 2.17
Prevalence of HIV infection among young adults in the United States: results from the Add Health study. Am J Public Health (2006) 2.17
Accelerating worldwide syphilis screening through rapid testing: a systematic review. Lancet Infect Dis (2010) 2.13
Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med (2009) 2.11
A multi-compartment, single and multiple dose pharmacokinetic study of the vaginal candidate microbicide 1% tenofovir gel. PLoS One (2011) 2.06
Keep them in school: the importance of education as a protective factor against HIV infection among young South African women. Int J Epidemiol (2008) 2.00
Amplified HIV transmission and new approaches to HIV prevention. J Infect Dis (2005) 1.95
The year-long effect of HIV-positive test results on pregnancy intentions, contraceptive use, and pregnancy incidence among Malawian women. J Acquir Immune Defic Syndr (2008) 1.94
Role of acute and early HIV infection in the sexual transmission of HIV. Curr Opin HIV AIDS (2010) 1.89
Improved detection of acute HIV-1 infection in sub-Saharan Africa: development of a risk score algorithm. AIDS (2007) 1.89
HIV incidence among men who have sex with men in China: a meta-analysis of published studies. PLoS One (2011) 1.79
Undisclosed antiretroviral drug use in a multinational clinical trial (HIV Prevention Trials Network 052). J Infect Dis (2013) 1.77
Drug interactions with new and investigational antiretrovirals. Clin Pharmacokinet (2009) 1.77
HIV treatment as prevention: debate and commentary--will early infection compromise treatment-as-prevention strategies? PLoS Med (2012) 1.76
Antiviral agents and HIV prevention: controversies, conflicts, and consensus. AIDS (2012) 1.73
Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. J Infect Dis (2011) 1.70
Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. Hepatology (2006) 1.69
Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost? Clin Infect Dis (2011) 1.68
Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 1.67
HIV treatment as prevention: to be or not to be? J Acquir Immune Defic Syndr (2010) 1.59
Development and validation of a PCR-based enzyme-linked immunosorbent assay with urine for use in clinical research settings to detect Trichomonas vaginalis in women. J Clin Microbiol (2002) 1.58
Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog (2011) 1.57
Protein binding of lopinavir and ritonavir during 4 phases of pregnancy: implications for treatment guidelines. J Acquir Immune Defic Syndr (2013) 1.56
Relative resistance of HIV-1 founder viruses to control by interferon-alpha. Retrovirology (2013) 1.55
HIV treatment as prevention: the utility and limitations of ecological observation. PLoS Med (2012) 1.55
The pharmacokinetics and viral activity of tenofovir in the male genital tract. J Acquir Immune Defic Syndr (2008) 1.55
Targeted screening for Trichomonas vaginalis with culture using a two-step method in women presenting for STD evaluation. Sex Transm Dis (2004) 1.54
Addition of treatment for trichomoniasis to syndromic management of urethritis in Malawi: a randomized clinical trial. Sex Transm Dis (2003) 1.52
China's syphilis epidemic: epidemiology, proximate determinants of spread, and control responses. Curr Opin Infect Dis (2011) 1.52
Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS Comput Biol (2010) 1.51
HIV-1 Populations in Semen Arise through Multiple Mechanisms. PLoS Pathog (2010) 1.47
Protease inhibitor and nonnucleoside reverse transcriptase inhibitor concentrations in the genital tract of HIV-1-infected women. J Acquir Immune Defic Syndr (2004) 1.45
Community viral load as a measure for assessment of HIV treatment as prevention. Lancet Infect Dis (2013) 1.43
Cisapride: a potential model substrate to assess cytochrome P4503A4 activity in vivo. Clin Pharmacol Ther (2003) 1.42
Factors related to female sex workers' willingness to utilize VCT service: a qualitative study in Jinan city, northern China. AIDS Behav (2008) 1.42
Continued high risk sexual behavior following diagnosis with acute HIV infection in South Africa and Malawi: implications for prevention. AIDS Behav (2011) 1.41
Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr (2006) 1.40
Generalizability and scalability of HIV 'treatment as prevention'. AIDS (2013) 1.39
Validation of a urine-based PCR-enzyme-linked immunosorbent assay for use in clinical research settings to detect Trichomonas vaginalis in men. J Clin Microbiol (2003) 1.34
Methods for detection of Trichomonas vaginalis in the male partners of infected women: implications for control of trichomoniasis. J Clin Microbiol (2006) 1.33
Preexposure prophylaxis for HIV--where do we go from here? N Engl J Med (2012) 1.33
Can antiretroviral therapy be used to prevent sexual transmission of human immunodeficiency virus type 1? Clin Infect Dis (2002) 1.33
Statistical considerations for the HPTN 052 Study to evaluate the effectiveness of early versus delayed antiretroviral strategies to prevent the sexual transmission of HIV-1 in serodiscordant couples. Contemp Clin Trials (2012) 1.33
Common human genetic variants and HIV-1 susceptibility: a genome-wide survey in a homogeneous African population. AIDS (2011) 1.33
Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy. PLoS One (2011) 1.32
Potential effect of HIV type 1 antiretroviral and herpes simplex virus type 2 antiviral therapy on transmission and acquisition of HIV type 1 infection. J Infect Dis (2005) 1.31
Dynamic antibody specificities and virion concentrations in circulating immune complexes in acute to chronic HIV-1 infection. J Virol (2011) 1.28
Full validation of an analytical method for the HIV-protease inhibitor atazanavir in combination with 8 other antiretroviral agents and its applicability to therapeutic drug monitoring. Ther Drug Monit (2006) 1.28
Policies and politics that promote HIV infection in the Southern United States. AIDS (2014) 1.28
Highly efficient HIV transmission to young women in South Africa. AIDS (2007) 1.28